Recent Updates
Recently added Catalysts
MIST Positive Sentiment

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Milestone Pharmaceuticals reported a positive corporate update, highlighting that over 50% of commercially insured lives in the U.S. now have coverage for their CARDAMYST nasal spray. This marks a significant increase in coverage for the Phase 3 registrational trial of etripamil for treating atrial fibrillation with rapid ventricular rate. Additionally, the activation of the first clinical sites is a notable advancement for the trial.

Market Sentiment Analysis

POSITIVE FACTORS

  • Over 50% of commercially insured lives in the U.S. now have coverage for CARDAMYST.
  • Significant increase in coverage for the Phase 3 trial.
  • First clinical sites for etripamil have been activated.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+75%
120-day peak, hindsight
Typical move
16.3%
average across 5 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
CX11
Phase 1 · Obesity & Overweight

Full Press Release Details

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) first clinical sites activated,

Frequently Asked Questions

What is CARDAMYST?

CARDAMYST is a nasal spray formulation of etripamil used for treating atrial fibrillation.

What recent milestone did Milestone Pharmaceuticals achieve?

Milestone Pharmaceuticals achieved over 50% coverage for CARDAMYST among commercially insured lives.

What trial is associated with etripamil?

Etripamil is currently in a Phase 3 registrational trial for atrial fibrillation with rapid ventricular rate.

Have clinical sites for etripamil been activated?

Yes, the first clinical sites for the etripamil trial have been activated.

ShareAdd on Google
Tags: MIST Viatris Investor Conferences Healthcare Milestone Pharmaceuticals etripamil CARDAMYST Phase 3 atrial fibrillation
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$171M liquidity · $9M/mo burn
~20 mo
Low dilution risk
Lead asset
CX11Phase 1
Obesity & Overweight →

Catalyst track record

+75%
best trade around MIST's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for MIST.

See every catalyst's timing & PoA →